Isenberg JS - Search Results

1

Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD. Soto-Pantoja DR, et al. Among authors: isenberg js. Expert Opin Ther Targets. 2013 Jan;17(1):89-103. doi: 10.1517/14728222.2013.733699. Epub 2012 Oct 27. Expert Opin Ther Targets. 2013. PMID: 23101472 Free PMC article. Review.

2

Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor.

Isenberg JS, Calzada MJ, Zhou L, Guo N, Lawler J, Wang XQ, Frazier WA, Roberts DD. Isenberg JS, et al. Matrix Biol. 2005 Apr;24(2):110-23. doi: 10.1016/j.matbio.2005.01.002. Epub 2005 Mar 17. Matrix Biol. 2005. PMID: 15890262

3

Nitric oxide in wound-healing.

Isenberg JS, Ridnour LA, Espey MG, Wink DA, Roberts DD. Isenberg JS, et al. Microsurgery. 2005;25(5):442-51. doi: 10.1002/micr.20168. Microsurgery. 2005. PMID: 16044466 Review.

4

Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1.

Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Ridnour LA, et al. Among authors: isenberg js. Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13147-52. doi: 10.1073/pnas.0502979102. Epub 2005 Sep 2. Proc Natl Acad Sci U S A. 2005. PMID: 16141331 Free PMC article.

5

Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner.

Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Isenberg JS, et al. Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13141-6. doi: 10.1073/pnas.0502977102. Epub 2005 Sep 6. Proc Natl Acad Sci U S A. 2005. PMID: 16150726 Free PMC article.

6

Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1.

Zhou L, Isenberg JS, Cao Z, Roberts DD. Zhou L, et al. Among authors: isenberg js. Oncogene. 2006 Jan 26;25(4):536-45. doi: 10.1038/sj.onc.1209069. Oncogene. 2006. PMID: 16247480

7

Guanylyl cyclase-dependent chemotaxis of endothelial cells in response to nitric oxide gradients.

Isenberg JS, Ridnour LA, Thomas DD, Wink DA, Roberts DD, Espey MG. Isenberg JS, et al. Free Radic Biol Med. 2006 Mar 15;40(6):1028-33. doi: 10.1016/j.freeradbiomed.2005.10.053. Epub 2005 Nov 17. Free Radic Biol Med. 2006. PMID: 16540398

8

Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses.

Isenberg JS, Wink DA, Roberts DD. Isenberg JS, et al. Cardiovasc Res. 2006 Sep 1;71(4):785-93. doi: 10.1016/j.cardiores.2006.05.024. Epub 2006 May 27. Cardiovasc Res. 2006. PMID: 16820142

9

CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1.

Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. Isenberg JS, et al. J Biol Chem. 2006 Sep 8;281(36):26069-80. doi: 10.1074/jbc.M605040200. Epub 2006 Jul 11. J Biol Chem. 2006. PMID: 16835222 Free article.

10

The biphasic nature of nitric oxide responses in tumor biology.

Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, Isenberg JS. Ridnour LA, et al. Among authors: isenberg js. Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1329-37. doi: 10.1089/ars.2006.8.1329. Antioxid Redox Signal. 2006. PMID: 16910780 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

189 results

Search Page